ClinicalTrials.Veeva

Menu
P

Panax Clinical Research | Miami Lakes, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SEL-212
BI 685509
ALT-801
Plozasiran
Nitazoxanide
HU6
Amisulpride
Relamorelin
Tirzepatide
RDX013

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

16 of 51 total trials

A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function

The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body...

Enrolling
Chronic Hepatitis D Infection
Drug: Bulevirtide (BLV)
Locations recently updated

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in hea...

Enrolling
Hepatic Impairment
Healthy Volunteers
Drug: Repotrectinib

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting
COVID-19
Influenza
Biological: COVID-19 Vaccine
Biological: Investigational influenza vaccine
Locations recently updated

This study is open to adults who are at least 18 years old and have* presumed or confirmed NASH together with overweight or obesity and* a body mass...

Enrolling
Non-Alcoholic SteatoHepatitis (NASH)
Obesity
Drug: Survodutide
Drug: Placebo

A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver...

Active, not recruiting
Nonalcoholic Steatohepatitis (NASH)
Type 2 Diabetes
Drug: Placebo
Drug: HTD1801

The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID...

Enrolling
COVID-19
SARS-CoV2 Infection
Drug: Placebo
Drug: IMM-BCP-01

A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to evaluate the pharmacokinetics (PK) and pharmacodynamics...

Enrolling
Hyperuricemia
Gout
Drug: allopurinol
Drug: dontinurad

This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose levels of HU6 in subjects with nonalcoholic steatohepat...

Active, not recruiting
Fatty Liver
Nonalcoholic Steatohepatitis
Drug: HU6
Other: Placebo

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). A...

Enrolling
Hypertriglyceridemia
Drug: Placebo
Drug: Plozasiran Injection

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (stea...

Enrolling
Non Alcoholic Steatohepatitis (NASH)
Drug: AXA1125
Drug: Placebo

The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with st...

Active, not recruiting
Rotator Cuff Tendinopathy
Drug: Secukinumab
Drug: Placebo

This is a double-blinded, two-arm, phase II study to assess efficacy, safety and tolerability of DFV890 in participants with symptomatic knee osteoar...

Enrolling
Symptomatic Knee Osteoarthritis
Drug: Placebo
Drug: DFV890

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (...

Enrolling
Severe Hypertriglyceridemia
Drug: Plozasiran Injection
Drug: Placebo

This is a non-randomized, open-label, single arm, self-controlled study of XP-8121 (levothyroxine sodium) to determine a target dose conversion facto...

Active, not recruiting
Hypothyroidism
Drug: levothyroxine sodium

The purpose of this study is to assess the drug levels and safety of BMS-986278 in participants with mild, moderate, and severe Hepatic Impairment (H...

Enrolling
Hepatic Impairment
Healthy Participants
Drug: BMS-986278

Trial sponsors

Boehringer Ingelheim logo
Lilly logo
Allergan logo
Novartis logo
Pfizer logo
A
A
Arrowhead Pharmaceuticals logo
A
BioNTech logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems